RxDoctor Payments Data

Michael Devereaux, MD

Internal Medicine · San Diego, CANPI 1922038512

Payments from drug & device makers

$1,915in general payments, 2019–2025

Across 128 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$603
  • Abbott$82
  • Johnson & Johnson$80
  • EMD Serono, Inc.$32
  • GSK$25
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$1,86497%
  • Education$523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,915 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$108,294
Medicare patients
169
Services billed
2,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala33$134,639
TivicayDolutegravir Sodium39$106,347
TriumeqAbacavir/Dolutegravir/Lamivudi15$97,099
JulucaDolutegravir/Rilpivirine15$60,001
OzempicSemaglutide31$48,630
DovatoDolutegravir Sodium/Lamivudine11$32,915
XareltoRivaroxaban21$32,016
EliquisApixaban40$27,757
Isentress HdRaltegravir Potassium11$24,225
RybelsusSemaglutide14$23,661
JanuviaSitagliptin Phosphate21$20,039
MounjaroTirzepatide12$12,460
Fluvastatin ErFluvastatin Sodium14$2,930
Nevirapine ErNevirapine22$2,773
Rosuvastatin Calcium192$2,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Triumeq, Juluca, Dovato$1,057$296,36280 claims
GileadBiktarvy$603$134,63933 claims
Novo NordiskOzempic, Rybelsus$22$72,29145 claims
Johnson & JohnsonXarelto$80$32,01621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →